Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other Accumulated Expenses: 2014-2024

Historic Other Accumulated Expenses for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $17.1 million.

  • Viking Therapeutics' Other Accumulated Expenses fell 14.97% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year decrease of 14.97%. This contributed to the annual value of $17.1 million for FY2024, which is 51.44% up from last year.
  • Per Viking Therapeutics' latest filing, its Other Accumulated Expenses stood at $17.1 million for FY2024, which was up 51.44% from $11.3 million recorded in FY2023.
  • Viking Therapeutics' 5-year Other Accumulated Expenses high stood at $17.1 million for FY2024, and its period low was $7.3 million during FY2021.
  • Over the past 3 years, Viking Therapeutics' median Other Accumulated Expenses value was $13.1 million (recorded in 2022), while the average stood at $13.8 million.
  • In the last 5 years, Viking Therapeutics' Other Accumulated Expenses soared by 93.15% in 2020 and then dropped by 13.84% in 2023.
  • Over the past 5 years, Viking Therapeutics' Other Accumulated Expenses (Yearly) stood at $7.8 million in 2020, then dropped by 6.48% to $7.3 million in 2021, then surged by 79.52% to $13.1 million in 2022, then declined by 13.84% to $11.3 million in 2023, then surged by 51.44% to $17.1 million in 2024.